title: iTRAQ-based quantitative proteomics reveals myoferlin as a novel prognostic predictor in pancreatic adenocarcinoma.
abstract: Histological differentiation is a major pathological parameter associated with poor prognosis in patients with pancreatic adenocarcinoma (PAC) and the molecular signature underlying PAC differentiation may involve key proteins potentially affecting the malignant characters of PAC. We aimed to identify the proteins which could be implicated in PAC prognosis. We used isobaric tags for relative and absolute quantitation (iTRAQ) coupled with two-dimensional liquid chromatography-tandem mass spectrometry to compare protein expression in PAC tissues with different degrees of histological differentiation. A total of 1623 proteins were repeatedly identified by performing the iTRAQ-based experiments twice. Of these, 15 proteins were differentially expressed according to our defined criteria. Myoferlin (MYOF) was selected to validate the proteomic results by western blotting. Immunohistochemistry in a further 154 PAC cases revealed that myoferlin significantly correlated with the degree of histological differentiation (P=0.004), and univariate and multivariate analyses indicated that MYOF is an independent prognostic factor for survival (hazard ratio, 1.540; 95% confidence interval, 1.061-2.234; P=0.023) of patients with PAC after curative surgery. RNA interference-mediated knockdown of MYOF alleviated malignant phenotypes of both primary and metastatic PAC cell lines in vitro and in vivo. Thus, ITRAQ-based quantitative proteomics revealed the prognostic value of MYOF in PAC.
  
  
  CONCLUSIONS
  Our results provide the possibility of novel strategies for pancreatic adenocarcinoma management.
authors.affiliation: Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China; Shanghai Medical Imaging Institute, Shanghai, 200032, China.
authors.forename: Wan-Sheng
authors.initials: WS
authors.lastname: Wang
authors.forename: Xiao-Hui
authors.initials: XH
authors.lastname: Liu
authors.forename: Ling-Xiao
authors.initials: LX
authors.lastname: Liu
authors.forename: Wen-Hui
authors.initials: WH
authors.lastname: Lou
authors.forename: Da-Yong
authors.initials: DY
authors.lastname: Jin
authors.forename: Peng-Yuan
authors.initials: PY
authors.lastname: Yang
authors.forename: Xiao-Lin
authors.initials: XL
authors.lastname: Wang
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000378:metabolism*; D000368:Aged; D000818:Animals; D017209:Apoptosis; D002135:Calcium-Binding Proteins / Q000378:metabolism*; D045744:Cell Line, Tumor; D002465:Cell Movement; D049109:Cell Proliferation; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism*; D051379:Mice; D008807:Mice, Inbred BALB C; D008875:Middle Aged; D009124:Muscle Proteins / Q000378:metabolism*; D009368:Neoplasm Transplantation; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D010641:Phenotype; D011379:Prognosis; D040901:Proteomics; D034622:RNA Interference
chemical_list: D002135:Calcium-Binding Proteins; C415584:MYOF protein, human; D008565:Membrane Proteins; D009124:Muscle Proteins; C521810:myoferlin protein, mouse
keywords: Myoferlin; Pancreatic neoplasms; Prognosis; Proteomics; iTRAQ